Switching GLP-1 RA to Maridebart Cafraglutide in Adults with Obesity or Overweight

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 trial examines the efficacy, safety, and tolerability of switching patients from a weekly GLP-1 receptor agonist to maridebart cafraglutide. Eligible adults have BMI ≥25 and achieved ≥10% weight loss on a GLP-1 RA, with stable weight and GI tolerance, and are willing to follow trial procedures. The study will monitor weight-related outcomes and adverse events to determine if the switch provides continued or improved weight management. Participants will be recruited at multiple sites and followed for the trial duration under close medical supervision.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Body Mass Index (BMI) ≥ 25 at screening.
* Weight loss of ≥ 10% on weekly GLP-1 RA.
* Stable body weight.
* Stable dose of GLP-1RA.
* Stable gastrointestinal (GI) tolerability.
* Contraception for females.
* Willingness to follow trial procedures for the duration of the trial.

Exclusion Criteria:

* Obesity induced by other endocrine disorders (ex: Cushing's syndrome).
* Previous or planned surgical, endoscopic or device-based treatment for obesity.
* History of malignancy.
* Type 1/Type 2 diabetes mellitus (DM).
* Family or personal history of medullary thyroid cancer.
* Previous participation in a Maridebart Cafraglutide trial.

Where it's running

• Cahaba Research, Inc.
  Pelham, Alabama, United States Recruiting
• Arizona Clinical Trials
  Chandler, Arizona, United States Recruiting
• Epic Medical Research - Sun City
  Sun City, Arizona, United States Recruiting
• Clinical Research Institute of Arizona LLC
  Sun City West, Arizona, United States Recruiting
• Peninsula Research Associates
  Chula Vista, California, United States Recruiting
• Desert Oasis Healthcare Medical Group
  Palm Springs, California, United States Recruiting

+7 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Amgen Call Center
• Email: medinfo@amgen.com
• Phone: 866-572-6436

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Petrelintide for weight management in adults with overweight or obesity

  This study tests whether petrelintide helps people with overweight or obesity lose weight when combined with a reduced-calorie diet and more exercise, compared with a placebo.

  Recruiting at 8 sites Phase 3 Hoffmann-La Roche · Anniston, Alabama and 7 other locations · NCT07843498

• Petrelintide for weight management in adults with overweight/obesity and type 2 diabetes

  This study tests whether petrelintide, added to a reduced-calorie diet and more physical activity, helps people with overweight or obesity and type 2 diabetes lose weight more effectively than a placebo.

  Recruiting at 2 sites Phase 3 Hoffmann-La Roche · Los Angeles, California and 1 other locations · NCT07843485

• Petrelintide for weight loss in people with overweight/obesity and heart disease

  This study tests whether petrelintide helps people with overweight or obesity and cardiovascular disease lose weight when added to a reduced-calorie diet and more physical activity, compared with a placebo.

  Recruiting at 3 sites Phase 3 Hoffmann-La Roche · Anniston, Alabama and 2 other locations · NCT07843472

• AZD6234: a new weekly shot to help adults lose weight

  This Phase 3 trial tests whether AZD6234 helps adults with obesity or overweight and weight-related health issues lose weight compared to placebo.

  Recruiting at 76 sites Phase 3 AstraZeneca · Dothan, Alabama and 219 other locations · NCT07784725

• AZD6234: a new option for adults with type 2 diabetes and excess weight

  A phase 3 trial tests whether AZD6234 helps adults with type 2 diabetes and overweight or obesity more than placebo over about 68 weeks.

  Recruiting at 58 sites Phase 3 AstraZeneca · Fairhope, Alabama and 229 other locations · NCT07784270

• AZD6234 added to current diabetes therapy to help with weight loss in adults who are overweight or have obesity

  This study tests whether AZD6234, when added to a person’s current incretin-based weight management therapy, can help adults with obesity or overweight lose more weight than a placebo over about 68 weeks.

  Recruiting at 56 sites Phase 3 AstraZeneca · Escondido, California and 95 other locations · NCT07776509

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.